BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 06, 2007
 |  BioCentury  |  Emerging Company Profile

Anaptys: Naturalizing antibodies

Using existing methods to isolate therapeutic antibodies with the desired biological activity can be lengthy, complicated and expensive. By harnessing natural biological mechanisms for creating antibody diversity, Anaptys Biosciences Inc. believes its Omnitope-SHM platform offers speed, cost effectiveness and technical advantages for both the discovery and optimization of therapeutic antibodies in a one-step process.

The company is using the technology to generate antibodies for its own account and also plans to conduct discovery and optimization against targets selected by partners.

"With many of the original players having been acquired or their technologies exclusively licensed for particular targets, and given certain technical limitations and complex IP and payment-stacking implications associated...

Read the full 523 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >